ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE




Dr Muhammad Arshad, Dr Zia Ullah, Dr Shahab Falak


History: Hepatitis C virus (HCV) infection rate is rising in the underdeveloped world and genotype III is the 2nd most common subtype to involve. Sofosbuvir has shown good results in the recent times. Objective: The aim of our study is to determine the efficacy of sofosbuvir for the treatment of hepatitis c genotype III. Study Design: This was a descriptive case series study Place and duration of Study: The study was conducted in medical wards of Lady Reading Hospital, Peshawar from January 2019 to December 2019. Methodology: The cases of HCV infection of genotype III assessed by PCR were included. These cases then were treated with oral sofosbuvir in a dose of 400 mg daily along with RBV with age appropriate doses. The efficacy was labelled as yes when there was negative result on PCR done at completion of 3 months. Results: In the present study there were total 200 patients that had HCV PCR positive for genotype III, out of which 112 (56%) were males and 88 (44%) were females with mean age of 46.21±4.27 years. Efficacy of sofosbuvir was seen in 184 (92%) of the patients. This efficacy was better in those that had age 50 or less where it was seen in 118 (94.4%) of cases as compared to 66 (88%) with age more than this (p=0.07). The duration of HCV less than 1 year revealed success rate of 96.67% as compared to 90% with p value of 0.08. Conclusion: Sofosbuvir has shown a very high efficacy rate in cases with HCV infection due to genotype III and results were near significantly better in those that had age less than 50 years and infection for less than 1 year. Keywords: HCV, Genotype III, Sofosbuvir.

  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.